End of the line for cannabinoid receptor 1 as an anti-obesity target?
A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.
Jones
Dan
D
D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D063385:Cannabinoid Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D020372:Dexfenfluramine / Q000009:adverse effects / Q000627:therapeutic use; D004435:Eating / Q000187:drug effects; D006801:Humans; D008019:Life Style; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000187:drug effects*; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000187:drug effects; D000077285:Rimonabant; D018570:Risk Assessment; D012307:Risk Factors
D019440:Anti-Obesity Agents; D063385:Cannabinoid Receptor Modulators; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D020372:Dexfenfluramine; D000077285:Rimonabant